Drug Profile
Tiotropium bromide - Orion
Alternative Names: Easyhaler tiotropium; Tiotropium bromide inhalation - Orion; Tiotropium bromide monohydrate - OrionLatest Information Update: 25 Oct 2022
Price :
$50
*
At a glance
- Originator Orion
- Class Antiasthmatics; Antibronchitics; Epoxy compounds; Esters; Small molecules; Thiophenes; Tropanes
- Mechanism of Action Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 20 Oct 2022 Discontinued - Phase-I for Chronic obstructive pulmonary disease (In volunteers) in Finland (Inhalation)
- 03 Aug 2022 Orion completes a phase-I TEMPO trial for Chronic obstructive pulmonary disease (In volunteers) in Finland (Inhalation) in August 2022 (NCT05246046)
- 18 Feb 2022 Orion plans a phase I pharmacokinetics trial in healthy volunteers in Finland, in February 2022 (Inhalation) (NCT05246046)